Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Raymond James

Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022

Benzinga

5 Walmart Analysts React To Mixed Q1 Earnings: 'Particularly Attractive Buying Opportunity'

Walmart Inc (NYSE: WMT) shares were in the clearance aisle Wednesday after the company reported rising costs related to supply chain problems and inflation in the first quarter.

Benzinga

Check Out What Whales Are Doing With CVX

Someone with a lot of money to spend has taken a bullish stance on Chevron (NYSE:CVX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Read Why Did Raymond James Slash Price Target On Inflarx

Raymond James remains a Strong Buy on Inflarx NV (NASDAQ: IFRX) following 1Q22 earnings based on a promising outlook for vilobelimab in Pyoderma Gangrenosum (PG) and potentially other indications. The biotech macro backdrop has forced many companies to be prudent with cash runway and prioritize clinical programs. InflaRx is also focusing on a potential pivotal trial…

Benzinga

Check Out What Whales Are Doing With CVX

Benzinga

Raymond James Maintains Outperform Rating for MeridianLink: Here's What You Need To Know

Raymond James has decided to maintain its Outperform rating of MeridianLink (NYSE:MLNK) and lower its price target from $27.00 to $21.00. Shares of MeridianLink are trading up 12.15% over the last 24 hours, at $16.25 per share.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022

Upgrades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Raymond James Sees 'Pipeline Key Success Factor' For This MedTech Stock

Raymond James has reiterated Outperform rating on LumiraDx Limited's (NASDAQ:LMDX) shares after 1Q revenue beat but lower than expected margins that ultimately do very little to impact long-term views of the company. They lowered the price target from $9 to $7. Revenues were 7% above Raymond James' view and 12% above consensus. The beat was…

Benzinga

Bumble Shares Soar On Analyst Confidence Post Q1 Beat

Analysts expressed optimism on Bumble Inc (NASDAQ: BMBL) post Q1 beat. Raymond James analyst Andrew Mar

Benzinga

Raymond James Says 'Supply Chain Challenges Made Q1 Messy' For This Medtech Stock

ICU Medical Inc (NASDAQ:ICUI) reported Q1 sales of $543.1 million vs. Raymond James' estimate of $530 million. Core ICU beat by $7 million, while newly acquired Smiths Medical missed by $5 million. With an Outperform rating, the analysts lowered the price target from $265 to $235. Adjusted EPS was $1.82, down from Raymond James' estimate…

Benzinga

Check Out What Whales Are Doing With DVN

A whale with a lot of money to spend has taken a noticeably bullish stance on Devon Energy. Looking at options history for Devon Energy (NYSE:DVN) we detected 15 strange trades.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022

Upgrades

Benzinga

10 Biggest Price Target Changes For Wednesday

Raymond James cut Electronic Arts Inc. (NASDAQ: EA) price target from $158 to $150. Electronic Arts shares rose 3.8% to $115.84 in pre-market trading.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

Upgrades

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

This Is What Whales Are Betting On Johnson & Johnson

A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 20 strange trades.

Benzinga

Analysts Expect Clarity Imminent On Intercept's NASH Story

RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA) in NASH, with REGENERATE re-analyses on deck, REVERSE reading in the next quarter. The analysts say it remains challenging to get visibility on how the efficacy/safety analyses will look,…

Benzinga

Raymond James Maintains Strong Buy Rating for Cushman & Wakefield: Here's What You Need To Know

Raymond James has decided to maintain its Strong Buy rating of Cushman & Wakefield (NYSE:CWK) and raise its price target from $32.00 to $35.00. Shares of Cushman & Wakefield are trading up 4.48% over the last 24 hours, at $19.00 per share.

Benzinga

Johnson & Johnson Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 10 strange trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Raymond James Maintains Outperform Rating for Upland Software: Here's What You Need To Know

Raymond James has decided to maintain its Outperform rating of Upland Software (NASDAQ:UPLD) and lower its price target from $30.00 to $24.00. Shares of Upland Software are trading down 10.11% over the last 24 hours, at $13.91 per share.

Benzinga

Chevron Whale Trades For May 05

Someone with a lot of money to spend has taken a bearish stance on Chevron (NYSE:CVX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Wells Fargo, Raymond James Highlighted Significant Angles To Skyworks Post Q2

Analyst views remain mixed post Skyworks Solutions, Inc's (NASDAQ: SWKS)

Benzinga

Lyft Analysts React To Q2 Guidance Miss, Heavy Investments In Lagging Driver Recovery

LYFT Inc (NASDAQ: LYFT) shares plummeted 32% on Wednesday after the company issued second-quarter guidance that came up well short of market expectations.

Benzinga

'Pent-Up Demand Driving Strength': Airbnb Analysts React To Q1 Earnings Beat

Airbnb Inc (NASDAQ: ABNB) shares traded higher by 4.9% on Wednesday after the company reported big first-quarter earnings growth and said it expects a sharp rebound in summer travel in 2022 as pandemic headwinds abate.

Benzinga

Raymond James Maintains Outperform Rating for Q2 Holdings: Here's What You Need To Know

Raymond James has decided to maintain its Outperform rating of Q2 Holdings (NYSE:QTWO) and lower its price target from $90.00 to $75.00. Shares of Q2 Holdings are trading down 6.59% over the last 24 hours, at $46.05 per share.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022

Upgrades

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.